You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Update references to 2022 and 2016 Guideline as appropriate
Full Name - 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain
Short Name - 2022 CDC Clinical Practice Guideline
If specifically referencing the 2016 Guideline, please use:
Full Name - CDC 2016 Guideline for Prescribing Opioids for Chronic Pain
Short Name - CDC 2016 Guideline
Update links to the 2022 Guideline as appropriate
Update the Recommendation 5 example, as the 2022 Recommendation 5 implementation is different from the 2016 version.
Consider possibly -
The MME calculator is expressed using Clinical Quality Language (CQL) and can be applied to Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR). A use case for this calculator is the 2022 CDC Clinical Practice Guideline Recommendation #8, which suggests that providers incorporate strategies to mitigate opioid therapy risks, including offering naloxone, when overdose risk such as “patients taking higher dosages of opioids (e.g., ≥50 MME/day)” is identified.
Update this narrative on the conversion factors page Section 3.1 “Usage” line 3 “Using the hard-coded conversion factors returned by the GetConversionFactor function, which are the same as the clinical conversion factors, including conversion factors for methadone (on a sliding scale by dose quantity) and transdermal fentanyl (given as a daily factor, specified with a standard patch duration of 3 days).” as a sliding scale is no longer used in the 2022 Guideline for methadone.
Update references to 2022 and 2016 Guideline as appropriate
Update links to the 2022 Guideline as appropriate
Update the Recommendation 5 example, as the 2022 Recommendation 5 implementation is different from the 2016 version.
Consider possibly -
The MME calculator is expressed using Clinical Quality Language (CQL) and can be applied to Health Level 7 (HL7) Fast Healthcare Interoperability Resources (FHIR). A use case for this calculator is the 2022 CDC Clinical Practice Guideline Recommendation #8, which suggests that providers incorporate strategies to mitigate opioid therapy risks, including offering naloxone, when overdose risk such as “patients taking higher dosages of opioids (e.g., ≥50 MME/day)” is identified.
Update conversion factors link used here - http://build.fhir.org/ig/cqframework/opioid-mme-r4/mme-calculator.html#:~:text=This%20results%20in,the%20specific%20drug to this link https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm?s_cid=rr7103a1_w#:~:text=TABLE.%20Morphine%20milligram%20equivalent%20doses%20for%20commonly%20prescribed%20opioids%20for%20pain%20management
Update this narrative on the conversion factors page Section 3.1 “Usage” line 3 “Using the hard-coded conversion factors returned by the GetConversionFactor function, which are the same as the clinical conversion factors, including conversion factors for methadone (on a sliding scale by dose quantity) and transdermal fentanyl (given as a daily factor, specified with a standard patch duration of 3 days).” as a sliding scale is no longer used in the 2022 Guideline for methadone.
Review the OMTK Data Processing page content to ensure that it is current http://build.fhir.org/ig/cqframework/opioid-mme-r4/omtkdata-processing.html
Review the Code System Supplement description here - http://build.fhir.org/ig/cqframework/opioid-mme-r4/CodeSystem-CDCMMEClinicalConversionFactors.html to ensure that it is current and appropriate
The text was updated successfully, but these errors were encountered: